PROTOKOLwiki
COMPOUNDS / STEROID / STANOZOLOL
STEROID

STANOZOLOL

HIGH RISK
BEST FOR:Cutting●●●●●●○○○○6/10
STANOZOLOL · WINSTROL · WINSTROL DEPOT · STROMBA · WINNY · ANDROSTANAZOL · STROMBAFORT · STANOZOL · MENABOL · NEURABOL
Anabolic SteroidDHT DerivativeCutting17-Alpha AlkylatedPerformance EnhancingHepatotoxic

Synthetic DHT-derivative anabolic steroid with high anabolic-to-androgenic ratio, used for cutting and strength but carries significant hepatotoxicity risk.

ROUTE / DOSAGE
LOW10mg
STANDARD25-50mg
HIGH100mg+
Note: 17-alpha alkylated - hepatotoxicity risk increases with dose and duration; limit to 6-8 weeks
CYCLE
6-8 weeks max 8 weeks due to hepatotoxicity
BIOAVAILABILITY
~10% oral ~100% IM
ACTIVE DURATION
8-12h oral 24-48h IM (subjective)
STORAGE
Room temperature dry away from light protect from moisture
HALF-LIFE
9h oral 24h IM (plasma)
DURATION BREAKDOWN
Total8-12 hours
Onset1-2 hours
Come up1-2 hours
Peak3-5 hours
Offset3-5 hours
After effects12-24 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Increased strength
Enhanced nitrogen retention
Reduced SHBG levels
Improved muscle hardness
Fibrinolytic activity
Androgenic effects
No estrogenic activity
§ 02 — RISKS
Hepatotoxicity including cholestasis and hepatic failure
Adverse lipid changes (reduced HDL, elevated LDL)
Joint discomfort due to reduced synovial fluid
Virilization in females
Cardiovascular strain
Suppression of endogenous testosterone production
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Stanozolol is FDA-approved for hereditary angioedema and has been investigated for fibrinolytic properties, Raynaud's phenomenon, and lipodermatosclerosis. Animal studies demonstrate significant nitrogen retention with both oral and IM administration, with IM showing greater efficacy. Hepatotoxicity is well-documented across species, including bland cholestasis in humans and severe hepatic failure in cats. Anti-doping analysis shows metabolites detectable in urine for up to 28 days. Evidence for performance enhancement in humans relies largely on anecdotal reports rather than controlled trials, and the risk-benefit profile is unfavorable for most non-medical applications.

§ 06 — SOURCES
[1]
Stanozolol as a novel therapeutic agent in dermatology
pubmed.ncbi.nlm.nih.gov ↗
[2]
Stanozolol-induced bland cholestasis
pubmed.ncbi.nlm.nih.gov ↗
[3]
Stanozolol-N-glucuronide metabolites in human urine samples as suitable targets in terms of routine anti-doping analysis
pubmed.ncbi.nlm.nih.gov ↗
[4]
GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
pubmed.ncbi.nlm.nih.gov ↗
[5]
Stanozolol in Pediatrics
pubmed.ncbi.nlm.nih.gov ↗
[6]
Hereditary angioedema
pubmed.ncbi.nlm.nih.gov ↗
[7]
The effect of stanozolol on 15nitrogen retention in the dog
pubmed.ncbi.nlm.nih.gov ↗
[8]
Hepatotoxicity of stanozolol in cats
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT